Compounds and methods for treating candidiasis and aspergillus infections

Abstract

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.

1 - 76 . (canceled) 
     
     
         77 . A method of preventing or treating a human having oral or disseminated candidiasis or an  aspergillus  infection comprising administering to the human in need thereof an effective amount of a compound of Formula IV: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  and R 2  are, independently, —C(═NH)NH 2 , —(CH 2 ) n NH 2 , or —(CH 2 ) n NC(═NH)NH 2 , where n is 2, 3, or 4; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
         78 - 252 . (canceled) 
     
     
         253 . The method of  claim 77  wherein R 1  and R 2  are, independently, —C(═NH)NH 2 , —(CH 2 ) n NH 2 , or —(CH 2 ) n NC(═NH)NH 2 , where n is 2 or 3. 
     
     
         254 . The method of  claim 77  wherein R 1  and R 2  are, independently, —C(═NH)NH 2  or —(CH 2 ) n NH 2 , where n is 2 or 3. 
     
     
         255 . The method of  claim 77  wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         256 . The method of  claim 77  wherein the compound, or pharmaceutically acceptable salt thereof, that is administered to the human is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. 
     
     
         257 . The method of  claim 256  wherein the pharmaceutical composition is in a unit dosage form. 
     
     
         258 . The method of  claim 257  wherein the unit dosage form is a packaged preparation. 
     
     
         259 . The method of  claim 257  wherein the unit dosage form is a tablet or capsule. 
     
     
         260 . The method of  claim 77  wherein the human has oral or disseminated candidiasis infection. 
     
     
         261 . The method of  claim 77  wherein the human has an  aspergillus  infection.